<DOC>
	<DOCNO>NCT00516828</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Drugs use chemotherapy , cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving sorafenib together cytarabine may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose give sorafenib together cytarabine see well work treat old patient acute myeloid leukemia high-risk myelodysplastic syndrome .</brief_summary>
	<brief_title>Sorafenib Low Dose Cytarabine Treating Older Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - To determine recommend dose sorafenib tosylate cytarabine give combination elderly patient acute myeloid leukemia high-risk myelodysplastic syndrome suitable intensive chemotherapy . ( Phase I ) - To determine safety , tolerability , toxicity profile , dose-limiting toxicity patient treat regimen . ( Phase I ) - To estimate efficacy ( measure complete response rate ) patient treat regimen . ( Phase II ) - To describe toxic effect overall response rate ( complete partial ) patient treat regimen . ( Phase II ) - To evaluate potential correlate response translational research study include FLT-3 internal tandem duplication point mutation blast . ( Phase II ) OUTLINE : This multicenter study . - Phase I : Patients receive oral sorafenib tosylate twice daily day 2-28 cytarabine subcutaneously twice daily day 1-10 dose level assign registration . Doses drug escalate recommended dos combination determine . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients respond treatment receive 2 cycle response criterion meet . - Phase II : Patients receive sorafenib tosylate cytarabine phase I recommend dos combination determine phase I . Bone marrow ( blood ) sample collect baseline end course study treatment . Baseline sample analyze mutational status FLT-3 ( i.e. , internal tandem duplication [ ITD ] point mutation ) . After completion study treatment , patient follow 4 week every 3 month thereafter progression toxicity resolve .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia ( AML ) FAB criterion ( By morphology routine histochemistry confirm , possible , flow cytometric analysis surface immunophenotype ; coexpression lymphoid marker permit ) Highrisk myelodysplastic syndrome define IPSS category intermediate2 great Must consider unsuitable intensive chemotherapy regimens No documented CNS involvement PATIENT CHARACTERISTICS : ECOG performance status 02 AST ALT ≤ 2 time upper limit normal ( ULN ) Bilirubin normal Creatinine ≤ 1.2 time ULN OR creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history malignancy , except adequately treat nonmelanoma skin cancer , curatively treat situ carcinoma cervix , solid tumor curatively treat evidence disease ≥ 5 year No upper gastrointestinal condition would preclude compliance administration oral medication No serious illness medical condition would permit patient manage accord protocol , include follow : History significant neurologic psychiatric disorder would impair ability obtain consent Active , uncontrolled , serious infection Active peptic ulcer disease Evidence bleed diathesis No myocardial infarction within past 6 month No congestive heart failure No unstable angina No active cardiomyopathy unstable ventricular arrhythmia No poorly control hypertension ( e.g. , systolic BP ≥ 150 mm Hg diastolic BP ≥ 95 mm Hg ) No know hypersensitivity study drug components No preexist hypothyroidism prior enrollment unless patient euthyroid medication No neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : At least 2 day since prior hydroxyurea No prior chemotherapy No concurrent therapeutic dos ( ≥ 2 mg/day ) anticoagulant ( e.g. , warfarin ) Doses 2 mg/day give prophylaxis thrombosis accept provided INR ≤ 1.5 No concurrent experimental drug anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>